Decarboxylated osteocalcin, a possible drug for type 2 diabetes, triggers glucose uptake in MG63 cells

Figure 5 Effects of decarboxylated osteocalcin on the proliferation and alkaline phosphatase activity in MG63 cells. A: Histogram showing the effects of decarboxylated osteocalcin (dcOC) on MG63 cell proliferation. The absorbance value was measured at 24, 48, and 72 h; B: Alkaline phosphatase activity in MG63 cells after 72 h of incubation with different concentrations of dcOC. Significant differences (P < 0.01) were found between the dcOC treatment groups (3 ng/mL and 10 ng/mL) and the control group (0 ng/mL). The data are representative of three independent experiments performed in triplicate. ^aP < 0.05, ^bP < 0.01 vs the control group (0 ng/mL). dcOC: Decarboxylated osteocalcin; ALP: Alkaline phosphatase.